What is Replimune Group's AFS securities?

Replimune Group (REPL) reported AFS securities of $0 in Q4 2025.

What does AFS securities mean?

Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.

Replimune Group REPL AFS Securities

AFS Securities at other companies

Arcus BiosciencesRCUS

$54M+575%

Nektar TherapeuticsNKTR

$162.99M+7,973%

Oric Pharmaceuticals, Inc.ORIC

$137.78M+588%

GRAIL, Inc.GRAL

$820.38M+22.0%

Summit TherapeuticsSMMT

——

IncyteINCY

——

Other financials

Income statement

See full

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Balance sheet

See full

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Cash flow

See full

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Valuation

See full

Market cap$930.59M+28.6%

Enterprise value$885.15M+28.3%

Returns & leverage

See full

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostAllowanceForCreditLossExcludingAccruedInterest.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's afs securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Replimune Group's AFS securities?: Replimune Group (REPL) reported AFS securities of $0 in Q4 2025.
What does AFS securities mean?: Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.